Cargando…
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme
The therapeutic use of tyrosine kinase inhibitors (TKIs) represents one of the successful strategies for the treatment of glioblastoma (GBM). Pyrazolo[3,4-d]pyrimidines have already been reported as promising small molecules active as c-Src/Abl dual inhibitors. Herein, we present a series of pyrazol...
Autores principales: | Poggialini, Federica, Vagaggini, Chiara, Brai, Annalaura, Pasqualini, Claudia, Crespan, Emmanuele, Maga, Giovanni, Perini, Cecilia, Cabella, Noemi, Botta, Lorenzo, Musumeci, Francesca, Frosini, Maria, Schenone, Silvia, Dreassi, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966370/ https://www.ncbi.nlm.nih.gov/pubmed/36839775 http://dx.doi.org/10.3390/pharmaceutics15020453 |
Ejemplares similares
-
Sweet Cherry Extract as Permeation Enhancer of Tyrosine Kinase Inhibitors: A Promising Prospective for Future Oral Anticancer Therapies
por: Poggialini, Federica, et al.
Publicado: (2023) -
Progress towards Adjuvant Development: Focus on Antiviral Therapy
por: Brai, Annalaura, et al.
Publicado: (2023) -
Tenebrio molitor as a Simple and Cheap Preclinical Pharmacokinetic and Toxicity Model
por: Brai, Annalaura, et al.
Publicado: (2023) -
Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor
por: Contadini, Claudia, et al.
Publicado: (2023) -
The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma
por: Rango, Enrico, et al.
Publicado: (2022)